ARPA-H Funding, Brain Wearables, & Nanotech Biosensing | Longevity News Roundup — Week 10, 2026

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping longevity and proactive healthcare. From government-backed healthspan trials to next-generation brain wearables, smartphone-based health screening, ovarian longevity research, and nanotech biosensing, this episode connects science, innovation, and real-world impact.The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.Mainstream pharma is also advancing longevity research. Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity._____________________News & References:ARPA-H pours millions into healthspan-focused human trials → https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trialsWearable startup Temple secures $54m for brain monitoring → https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/YOU(th) lands funding for smartphone-based preventive health screening → https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/Richter sharpens ovarian aging focus following Celmatix asset deal → https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/How billionaires die → https://longevity.technology/news/how-billionaires-die/Nanotech startup lands funding for continuous biosensing platform → https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/_____________________Hosts:Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn